Pfizer Animal Health today announced that it has entered into an
agreement to acquire multiple product franchises from Schering-Plough
Corporation covering all major animal health species including cattle
swine, equine, and companion animal.
Specifically, Pfizer Animal Health will acquire from
Schering-Plough a number of animal health products for sale in the
European Economic Area covering the following categories:
-- Swine E. coli Vaccines
-- Equine Influenza and Tetanus Vaccines
-- Ruminant Neonatal and Clostridia Vaccines
-- Rabies Vaccines
-- Companion Animal Veterinary Specialty Products
-- Parasiticides & Anti-inflammatories
The acquisition is subject to certain closing conditions
including antitrust approval. Terms of the agreement were not
disclosed.
Pfizer Animal Health´s Europe President, Albert Bourla, said that
the acquisition will enable Pfizer Animal Health Europe to build upon
its comprehensive animal health solutions for veterinarians and their
clients - farmers and pet owners - in Europe. Bourla added, "We look
forward to offering veterinarians additional preventative therapies
and treatments along with our technical expertise and services to
ensure that animals receive the best care possible."
About Pfizer Animal Health
Pfizer Inc (NYSE: PFE), the world´s largest research-based
pharmaceutical company, is a world leader in discovering and
developing innovative animal vaccines and prescription medicines.
Pfizer Animal Health is dedicated to improving the safety, quality and
productivity of the world´s food supply by enhancing the health of
livestock and poultry; and in helping companion animals live longer
and healthier lives. For additional information on Pfizer´s portfolio
of animal products, visit www.PfizerAH.com.
DISCLOSURE NOTICE: The information contained in this release is as
of April 23, 2008. Pfizer assumes no obligation to update any
forward-looking statements contained in this release as the result of
new information or future events or developments. This release
contains forward-looking information about the agreement by Pfizer to
acquire certain animal health products from Schering-Plough that
involve substantial risks and uncertainties. Such risks and
uncertainties include, among others, the satisfaction of the
conditions to closing the agreement. A further list and description of
risks and uncertainties can be found in Pfizer´s Annual Report of Form
10-K for the fiscal year ended December 31, 2007 and in its reports on
Form 10-Q and Form 8-K.
